Genomic Health, Inc.  

(Public, NASDAQ:GHDX)   Watch this stock  
Find more results for ghdx
33.72
-0.14 (-0.41%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.41 - 34.02
52 week 26.37 - 34.02
Open 34.02
Vol / Avg. 95,695.00/140,844.00
Mkt cap 1.17B
P/E     -
Div/yield     -
EPS -0.15
Shares 34.65M
Beta 0.77
Inst. own 91%
Oct 30, 2017
Q3 2017 Genomic Health Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 6, 2017
Genomic Health Inc at Wells Fargo Healthcare Conference
Aug 1, 2017
Q2 2017 Genomic Health Inc Earnings Call - Webcast
Aug 1, 2017
Q2 2017 Genomic Health Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -3.20% -4.25%
Operating margin -3.68% -4.71%
EBITD margin - -1.98%
Return on average assets -5.30% -7.22%
Return on average equity -6.64% -9.42%
Employees 846 -
CDP Score - -

Address

301 Penobscot Dr
REDWOOD CITY, CA 94063-4700
United States - Map
+1-650-5569300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Officers and directors

Kimberly J. Popovits Chairman of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon Bradley Cole Chief Financial Officer, Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
Steven Shak M.D. Chief Scientific Officer
Age: 66
Bio & Compensation  - Reuters
Phillip Febbo M.D. Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Laura Leber Kammeyer Chief Communications Officer
Age: 54
Bio & Compensation  - Reuters
Frederic Pla Ph.D. Chief Business and Product Development Officer
Bio & Compensation  - Reuters
James Vaughn Chief Commercial Officer
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D. M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters